Article

Archives of Virology

, Volume 152, Issue 8, pp 1447-1455

First online:

Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo

  • L. ShiAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University
  • , H. XiongAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University
  • , J. HeAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University
  • , H. DengAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University
  • , Q. LiAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University
  • , Q. ZhongAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University
  • , W. HouAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University
  • , L. ChengAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University
  • , H. XiaoAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University
    • , Z. YangAffiliated withState Key Laboratory of Virology, Institute of Medical Virology, Wuhan University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

Arbidol, ethyl-6-bromo-4-[(dimethylamino)-methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-in dole-3-carboxylate hydrochloride monohydrate, is an antiviral chemical agent. In this report, we studied the antiviral activity of arbidol against a panel of human respiratory viruses, namely influenza A virus (FLU-A, A/PR/8/34 H1N1), respiratory syncytial virus (RSV), human rhinovirus type 14 (HRV 14), coxsackie virus B3 (CVB3) and adenovirus type 7 (AdV-7) in vitro in cell culture. Arbidol was found to present potent inhibitory activity against enveloped and non-enveloped RNA viruses, including FLU-A, RSV, HRV 14 and CVB3 when added before, during, or after viral infection, with 50% inhibitory concentration (IC50) ranging from 2.7 to 13.8 µg/ml. However, arbidol showed selective antiviral activity against AdV-7, a DNA virus, only when added after infection (therapeutic index (TI) = 5.5). Orally administered arbidol at 50 or 100 mg/kg/day beginning 24 h pre-virus exposure for 6 days significantly reduced mean pulmonary virus yields and the rate of mortality in mice infected with FLU-A (A/PR/8/34 H1N1). Our results suggest that arbidol has the ability to elicit protective broad-spectrum antiviral activity against a number of human pathogenic respiratory viruses.